(Q40806756)

English

Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis

scientific article published on 24 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

0 references

Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

E S Mearns

1

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

W J Saulsberry

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

C M White

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

C G Kohn

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

S Lemieux

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

A Sihabout

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

I Salamucha

7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

C I Coleman

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

publication date

24 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Diabetic Medicine

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

1530-1540

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Fate of the beta-cell in the pathophysiology of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Evaluation of inconsistency in networks of interventions

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Earlier triple therapy with pioglitazone in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Microalbuminuria: a parameter that has changed diabetes care

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Risk factors associated with acute pyelonephritis in healthy women

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12837

21 January 2018

Identifiers

10.1111/DME.12837

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40806756&oldid=1907784711"